We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drug developer Barr Pharmaceuticals Inc. said Tuesday it will start selling a generic version of its contraceptive Ovcon-35, after Warner Chilcott Ltd. waived the exclusivity provision of its license for the drug.
Par Pharmaceutical Cos., a generic-drug maker being scrutinized by U.S. regulators, said Tuesday that it named Patrick G. LePore, 51, as president and chief executive officer to replace Scott Tarriff, 47, who was fired.
Barr Pharmaceuticals Inc. confirmed Wednesday it is challenging the patents protecting Savient Pharmaceuticals Inc.'s Oxandrin CIII weight gain treatment.
A federal jury on Tuesday cleared Merck & Co. of being liable for the heart attack of a Kentucky man who took the company's Vioxx painkiller for less than five months.
ImClone Systems suffered a major legal defeat Sept. 18 when U.S. District Judge Naomi Reice Buchwald ruled that three Israeli scientists actually invented the cancer treatment the company sells under the trade name Erbitux.
Law enforcement currently takes too prominent of a role in setting off-label enforcement policy, necessitating regulations to establish more consistent policy, an industry attorney said.
Tomorrow activists will seek permission in federal court to gain access to White House documents and to depose a former administration adviser concerning the controversial contraceptive Plan B to determine whether the White House interfered in the FDA's decisionmaking on the drug.